Cargando…

Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of non-small cell lung cancer (NSCLC). Most randomized clinical trials have excluded patients with brain metastasis (BM), and real-life patients with NSCLC who receive ICIs are not routinely scanned with magne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bjørnhart, Birgitte, Hansen, Karin Holmskov, Asmussen, Jon Thor, Jørgensen, Trine Lembrecht, Herrstedt, Jørn, Schytte, Tine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997168/ https://www.ncbi.nlm.nih.gov/pubmed/35406453 http://dx.doi.org/10.3390/cancers14071682

Ejemplares similares

Impact of Age, Comorbidity, and FIGO Stage on Treatment Choice and Mortality in Older Danish Patients with Gynecological Cancer: A Retrospective Register-Based Cohort Study
por: Nadaraja, Sambavy, et al.
Publicado: (2018)

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
por: Mouritzen, Mette T., et al.
Publicado: (2021)

How to select cancer patients for immunotherapy
por: Pfeiffer, Per, et al.
Publicado: (2021)

Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT
por: Pan, Yi, et al.
Publicado: (2015)

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example
por: Winther, Stine Braendegaard, et al.
Publicado: (2016)

Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
por: Adam, Lucas C., et al.
Publicado: (2018)

Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis
por: Xie, Mengqing, et al.
Publicado: (2023)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting
por: Ruhlmann, Christina, et al.
Publicado: (2009)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
por: Zarogoulidis, Paul, et al.
Publicado: (2022)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?
por: Morabito, Alessandro
Publicado: (2018)

Improved understanding of NSCLC immunotherapy response mechanisms from single-cell analysis
por: Bienkowska, Kamila Justyna, et al.
Publicado: (2023)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Pleurodesis and Immunotherapy in NSCLC; Medical Thoracoscopy or VATS?
por: Zarogoulidis, Paul, et al.
Publicado: (2020)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
por: Roller, John F., et al.
Publicado: (2022)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
por: Lv, Lulu, et al.
Publicado: (2022)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
por: Goh, Kah Yee, et al.
Publicado: (2023)

Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality
por: Jørgensen, T L, et al.
Publicado: (2012)

NSCLC metastasis: going with ELMO3
por: Goyette, Marie-Anne, et al.
Publicado: (2014)

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes
por: Herrstedt, Jørn, et al.
Publicado: (2021)

P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.
por: Gundesen, Michael, et al.
Publicado: (2023)

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan
por: Nokihara, Hiroshi, et al.
Publicado: (2022)

Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?
por: Merkin, Ross D., et al.
Publicado: (2023)

Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC
por: Rossi, Alessandro, et al.
Publicado: (2021)

New modalities of cancer treatment for NSCLC: focus on immunotherapy
por: Davies, Marianne
Publicado: (2014)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

Co-occurring genomic alterations and immunotherapy efficacy in NSCLC
por: Zhang, Fan, et al.
Publicado: (2022)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC
por: Wang, Yuntao, et al.
Publicado: (2022)

Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Immunotherapy and Chemotherapy Versus Sleep Disturbances for NSCLC Patients
por: Zarogoulidis, Paul, et al.
Publicado: (2023)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5331vlvhjrm90m0jrj53kmm926